

IMPLEMENTING THE EU HEALTH TECHNOLOGY ASSESSMENT REGULATION

WHAT IS HTA?

HEALTH TECHNOLOGY ASSESSMENT:

Procedure for assessing the added value, effectiveness, costs and broader impact of health care interventions including medicines, medical devices and procedures.

- » Is a new medicine more effective in treating a certain disease?
- » Do expected costs and benefits present sufficient value-for-money when compared to alternative healthcare interventions?
- » How to compare a new medicine to an existing one considering patients, the disease, and the outcome for the patient?
- » Will the use of a new medical device result in better diagnosis or treatment?

HTA DOMAINS

CLINICAL DOMAINS



- » Health problems and currently used health technologies (e.g. medicines, medical devices, surgical procedures).
- » Description of health technology under assessment.
- » Relative clinical effectiveness.
- » Relative safety.

NON-CLINICAL DOMAINS



- » Economic evaluation.
- » Ethical aspects.
- » Organisational aspects.
- » Social aspects.
- » Legal aspects.

WHAT'S IN THE EU HTA REGULATION?



FRAMEWORK FOR JOINT HTA COOPERATION

- » Joint clinical assessments (JCAs).
- » Joint scientific consultations (JSCs).
- » Identification of emerging health technologies.
- » Common procedures and methodologies across the EU.



KEY PRINCIPLES OF THE HTA REGULATION

- » Only on clinical domains of the assessment: No economic assessment or any conclusion on pricing and reimbursement.
- » Driven by EU HTA bodies who remain responsible for drawing conclusions on added value for their health systems.
- » High quality, timeliness and transparency.
- » Use of joint work in national HTA processes.
- » Input from independent experts.
- » Stakeholder engagement and inclusiveness.
- » Progressive implementation.



TIMELINE FOR MEDICINES

- » 12 January 2025: New oncology medicines and advanced therapy medicinal products will be assessed at EU level.
- » 13 January 2028: Orphan medicinal products to be added to the joint work.
- » 13 January 2030: All new medicines will come under the scope of the regulation.